Trevi Therapeutics (TRVI) Competitors

Trevi Therapeutics (NASDAQ:TRVI) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

Which has higher valuation & earnings, TRVI or APLS?

Trevi Therapeutics has higher earnings, but lower revenue than Apellis Pharmaceuticals. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$47.91M	-$0.42	-17.98
Apellis Pharmaceuticals	$754.65M	4.68	-$197.88M	-$1.82	-15.37

Is TRVI or APLS more profitable?

Trevi Therapeutics has a net margin of 0.00% compared to Apellis Pharmaceuticals' net margin of -30.24%. Trevi Therapeutics' return on equity of -41.44% beat Apellis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-41.44%	-38.21%
Apellis Pharmaceuticals	-30.24%	-116.09%	-26.72%

Do analysts rate TRVI or APLS?

Trevi Therapeutics currently has a consensus target price of $20.11, indicating a potential upside of 166.37%. Apellis Pharmaceuticals has a consensus target price of $34.12, indicating a potential upside of 21.98%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Trevi Therapeutics is more favorable than Apellis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20
Apellis Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.58

Do insiders and institutionals believe in TRVI or APLS?

95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are held by institutional investors. 18.3% of Trevi Therapeutics shares are held by insiders. Comparatively, 6.5% of Apellis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Which has more risk & volatility, TRVI or APLS?

Trevi Therapeutics has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500.

Does the media refer more to TRVI or APLS?

In the previous week, Trevi Therapeutics had 2 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 10 mentions for Trevi Therapeutics and 8 mentions for Apellis Pharmaceuticals. Apellis Pharmaceuticals' average media sentiment score of 1.21 beat Trevi Therapeutics' score of 0.80 indicating that Apellis Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Apellis Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Trevi Therapeutics beats Apellis Pharmaceuticals on 9 of the 16 factors compared between the two stocks.